Last updated: January 9, 2024
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Overall Status: Active - Recruiting
Phase
N/A
Condition
Red Blood Cell Disorders
Platelet Disorders
Nephropathy
Treatment
Data collection from EHR.
Clinical Study ID
NCT06213402
PR(AMI)427/2021
Ages < 100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients must meet all of the following criteria to be included in the RADeep Registry
- Age from 0-100, both female and male
- Diagnosed as RADs (SCD, THAL, PKD, and other RADs THAL according to ORPHANETclassification)
- Able and willing to provide written informed consent (patient or legal representativefor minors)
Exclusion
Exclusion Criteria:
- Patient or legal representative for minors unwilling or unable to give consent
- Patients diagnosed with SCD or THAL (alpha-thalassaemia and beta-thalassaemia) traitsor trait conditions for other recessive RADs
Study Design
Total Participants: 32564
Treatment Group(s): 1
Primary Treatment: Data collection from EHR.
Phase:
Study Start date:
November 30, 2021
Estimated Completion Date:
November 30, 2036
Study Description
Connect with a study center
Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH)
Barcelona, Catalunya 08035
SpainActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.